Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Kosan BioSciences -- KOSN -- Ignore unavailable to you. Want to Upgrade?

To: quidditch who wrote (354)	9/26/2003 11:53:00 AM
From: scaram(o)uche	Read Replies (1) \| Respond to of 933

Dan Santi is running a class-act biotech at the bench. Otherwise, it's hilarious how management is going out of their way to earn the label "tacky". I know Ostrach from NTII, which was flown directly into the ground by management. I always assumed that he was a lone voice of reason at the company, but now I wonder. It's time that Santi et al. suck it up and start to behave like mature individuals. The modern day of biotech demands that you point at the goal of profit, while holding shares to command respect and attention. It seems impossible to muck up this business plan, given management with incentive. Why they want to send this "we'll take the money now, thanks!" message is beyond me.